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For scaling drug plasma clearance (CLp) from adults to children, extrapolations of population pharmacokinetic (PopPK)
covariate models between drugs sharing an elimination pathway have enabled accelerated development of pediatric models
and dosing recommendations. This study aims at identifying conditions for which this approach consistently leads to
accurate pathway specific CLp scaling from adults to children for drugs undergoing hepatic metabolism. A physiologically
based pharmacokinetic (PBPK) simulation workflow utilizing mechanistic equations defining hepatic metabolism was
developed. We found that drugs eliminated via the same pathway require similar pediatric dose adjustments only in specific
cases, depending on drugs extraction ratio, unbound fraction, type of binding plasma protein, and the fraction metabolized by
the isoenzyme pathway for which CLp is scaled. Overall, between-drug extrapolation of pediatric covariate functions for CLp
is mostly applicable to low and intermediate extraction ratio drugs eliminated by one isoenzyme and binding to human serum
albumin in children older than 1 month.
CPT Pharmacometrics Syst. Pharmacol. (2018) 00, 00; doi:10.1002/psp4.12273; published online on 0 Month 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Proofs of concept for extrapolation of pediatric covar-
iate functions for CLp between drugs sharing the same
elimination pathway have been published for a limited
number of drugs eliminated through glucuronidation
and renal excretion.
WHAT QUESTION DID THIS STUDY ADDRESS?
 The study identifies the conditions upon which
between-drug extrapolation of isoenzyme-specific pedi-
atric covariate functions consistently leads to accurate
CLp scaling from adults to pediatric ages for drugs
metabolized by one or multiple hepatic isoenzymes.
WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
 Between-drug extrapolation of pediatric covariate
functions for CLp is mostly applicable to low and inter-
mediate extraction ratio drugs eliminated by one isoen-
zyme and binding to human serum albumin in children
older than 1 month.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 We now have a tool available that can establish a
priori whether two drugs metabolized by the same iso-
enzyme will require the same or different dose adjust-
ments in pediatrics.
Accurate scaling of plasma clearance (CLp) of drugs from
adults to the pediatric population is crucial for the definition
of first-in-child doses and for the development of pediatric
dose recommendations.1–4 As illustrated in Figure 1, for
drugs undergoing hepatic metabolism, CLp values are
driven by the complex interplay between drug-specific and
system-specific properties. Relevant parameters to describe
hepatic clearance are hepatic blood flow (Qh), the unbound
drug fraction in plasma, the blood to plasma ratio (B:P),
and the intrinsic metabolic clearance in the liver based on
unbound drug concentration (CLint).5 The Qh is a purely
system-specific parameter, whereas unbound fraction, B:P,
and CLint are derived from both system-specific and drug-
specific parameters. Moreover, in children, system-specific
parameters vary with age due to ontogenic processes,
which in turn drive CLp changes across the pediatric age
range (Figure 1).6 Because physiologically based pharma-
cokinetic (PBPK) modeling integrates all the above-
mentioned information,6,7 it can provide a yardstick for
scaling drug CLp from adults to various pediatric ages in
the absence of pediatric clinical data,6,8–11 which is relevant
for first-in-child dose definition. In addition to PBPK model-
ing, there is a need for model-based scaling methods that
aggregate the influence of ontogeny of the system-specific
parameters in a smaller set of equations, thereby facilitating
scaling of pediatric CLp in drug development and clinical
practice.
In pediatric population pharmacokinetic (PopPK) models,
the net influence of ontogeny of system-specific parameters
on CLp of a drug is described using empirical covariate
models derived from clinical data (i.e., concentration-time
profiles). Although these covariate models can be directly
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used as the basis for pediatric dose adjustments,12–14 this
approach requires clinical data obtained upon the adminis-
tration of every single drug of interest in every pediatric
subpopulation.
Semimechanistic or semiphysiological PopPK pediatric
scaling approaches have been proposed to bridge the gap
between PBPK and PopPK methodologies, allowing for accel-
erated development of pediatric PopPK models and subse-
quent dosing recommendations. One of these approaches
relies on extrapolations of PopPK covariate models between
drugs that share an elimination pathway.15–19 Because PopPK
covariate models are the basis of dose recommendations, this
approach would also allow for extrapolation of pediatric dosing
recommendations from a drug of which the changes in clear-
ance have been quantified to other drugs for which no pediat-
ric pharmacokinetic (PK) studies have been undertaken
provided these drugs share the same elimination pathway. To
date, proofs of concept for this method have been published
for a limited number of drugs eliminated through glucuronida-
tion or renal excretion.15–19 However, as illustrated in Figure 2,
with this method, the between drug differences in CLp of
drugs sharing the same elimination pathway are solely
accounted for by the absolute value of the scaled CLp (e.g.,
adult CLp values), whereas CLp ontogeny is assumed to be
purely system-specific and, therefore, drug independent.
This assumption is challenged by the fact that CLp of drugs
with different properties might be impacted differently by the
various ontogenic changes in system-specific parameters
(Figure 1).
Therefore, the aim of the current study is to identify the
conditions for which between-drug extrapolation of pediatric
covariate functions for hepatic metabolic CLp consistently
leads to accurate pathway-specific CLp scaling from adults
to children of various ages (absolute prediction error 30%).
We developed a PBPK-based simulation workflow utilizing
mechanistic equations defining hepatic metabolism to sys-
tematically screen a wide parameter space for both system-
specific and drug-specific variables impacting hepatic CLp by
one specific isoenzyme. Additionally, we investigated the
impact of multiple elimination pathways on the between-drug
extrapolation potential of pediatric covariate functions for
hepatic metabolic CLp. This allowed us to define a decision
tree to identify the conditions leading to consistently accurate
pediatric CLp scaling using between-drug extrapolations of
pathway-specific pediatric covariate models.
METHODS
Model drug and test drug
Total (i.e., bound and unbound) hepatic metabolic plasma
clearance will be referred to as CLp in this paper. We inves-
tigate the extrapolation potential of pediatric covariate func-
tions scaling CLp from adults to pediatric patients between
a model drug and a test drug both exclusively eliminated by
the same hepatic isoenzyme. This method is illustrated in
Figure 2. The impact of elimination by multiple isoenzymes
is investigated as described under the section “Multiple
elimination pathways.”
• Model drug and determination of the pediatric covariate function: A
pediatric covariate function is developed to describe the ontogeny of
CLp of what will be referred to as the model drug (M).
• Test drug and between-drug extrapolation of the pediatric covariate
function: The pediatric covariate function developed based on the
model drug (M) is used to scale CLp for what will be referred to as
the test drug (T) from adults to various pediatric ages.
Figure 1 Schematic representation of the complex interplay between drug-specific and system-specific parameters driving hepatic CLp
values. Parameters within circles are directly used in the physiologically based pharmacokinetic hepatic clearance model (e.g., disper-
sion model). Parameters in the purple circles represent composite parameters that are derived from the system-specific parameters
and the drug-specific parameters indicated by the numbers in the subscripts. In children, each of the system-specific parameters
change with age, each represented by a lightning bolt. B:P, blood to plasma ratio; CLint, intrinsic metabolic clearance in the liver based
on unbound drug concentrations; fu, unbound drug fraction in plasma; MPPGL, microsomal protein per gram of liver.
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PBPK-based simulation workflow
A four-step PBPK-based simulation workflow (Figure 3)
was developed in R software20 version 3.3.1 with R studio
interface version 0.99.902 following a similar approach as
previously published.21 This workflow investigates the
impact of two main variables on the accuracy of pediatric
CLp predictions based on extrapolation of pediatric covari-
ate functions from a model drug to a test drug. These varia-
bles are the drug-specific parameters of both the model
drug and test drug and the ontogeny of the system-specific
parameters (Figure 1). This investigation was undertaken
for 15 different elimination pathways. These elimination
pathways correspond to elimination by the following isoen-
zymes: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C18_19, CYP2D6, CYP2E1, CYP3A4, UGT1A1,
UGT1A4, UGT1A6, UGT1A9, UGT2B7, and SULT1A1. Ulti-
mately, conditions for which extrapolations consistently led
to accurate CLp predictions were identified.
Figure 2 Illustration of between-drug extrapolation of pediatric covariate functions to scale hepatic plasma clearance (CLp) from adults
to pediatric patients for drugs eliminated by the same isoenzyme. The black dot in both graphs shows the adult hepatic CLp value for
the model drug (“true” adult CLp_M) and the test drug (“true” adult CLp_T). The solid black line represents the change in CLp of the
model drug throughout the pediatric age range, which is described by a pediatric covariate function based, in this example, on body-
weight (CLp ontogeny_M (bodyweight)). The dashed black line represents the scaled pediatric CLp predicted for the test drug by
between-drug extrapolation of the pediatric covariate function obtained for the model drug (CLp ontogeny_M (bodyweight)).
Figure 3 Physiologically based pharmacokinetic (PBPK)-based simulation workflow used to investigate the between-drug extrapolation
potential of pediatric covariate models when scaling total plasma clearance (CLp) from adults to pediatric patients. The model drug is
denoted with M and the test drug with T. AGE stands for pediatric postnatal age. All steps are performed for model drugs and test
drugs binding to the same plasma proteins and eliminated by the same isoenzyme and repeated for each of the 15 isoenzymes and
each of the 2 binding plasma proteins investigated.
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Variables in the PBPK-based simulation workflow. For a
systematic investigation of the impact of each variable, we
chose a factorial design (i.e., a global sensitivity analysis
approach) with a wide yet realistic parameter space for each
individual variable. For this purpose, continuous variables
were transformed into categorical variables using a number of
intermediate values within the defined parameter space allow-
ing for the generation of single point estimates of the different
functions of the PBPK-based simulation workflow. To enable
the computation across a wide parameter space and inter-
pretability of the results, variability and uncertainty in both
demographics and model parameters were not accounted for.
• Ontogeny of system-specific parameters:
To unravel the impact of ontogeny of the system-specific parame-
ters (see Figure 1) on the extrapolation potential of pediatric covari-
ate functions between drugs sharing the same elimination pathway,
simulations were performed for eight typical individuals for whom
demographic characteristics and system-specific parameters are
specified in Table 1. The PBPK model parameters for typical indi-
viduals were computed as average values of men and women.
Ontogeny functions for each system-specific model parameter were
taken from the Simcyp software (Simcyp, Sheffield, UK) V15.R1
library, except for the isoenzyme ontogeny of SULT1A1. For
SULT1A1, maturity was taken to have been reached at birth,22 and,
therefore, isoenzyme ontogeny of SULT1A1, defined as the pediatric
to adult ratio of microsomal intrinsic clearance, was set to 1. More
information can be found in Supplementary Material S1.
• Drug-specific properties of the model drugs and test drugs:
To unravel the impact of drug-specific properties on the between-
drug extrapolation potential of pediatric covariate functions, a total of
7,560 hypothetical drugs with unique combinations of drug-specific
properties were generated and used as model drugs, as well as
test drugs. This set of hypothetical drugs was generated using all
possible combinations of different values of the following three drug-
specific properties: adult unbound fraction in plasma (range: 0.01–1;
n5 10), blood-to-plasma partition coefficient or Kp (range: 0.35–40;
n5 9), and adult total unbound intrinsic clearance value of one
microgram of liver microsomes or adult CLint, mic, total (range:
0.561026 to 0.209.1023 L.min21.mg21 microsomal protein;
n5 42). The hypothetical drugs were assumed to be exclusively
bound to either human serum albumin (HSA) or alpha-1 acid
glycoprotein (AAG). More details can be found in Supplementary
Material S1.
Steps of the PBPK-based simulation workflow. Between-
drug extrapolation of covariate models was studied for
model and test drugs sharing the same elimination pathway
and binding to the same plasma protein. For each of the 15
elimination pathways investigated and each type of binding
plasma protein, the following steps were undertaken, as
also illustrated in Figure 3:
Table 1 Demographic characteristics of the eight typical individuals implemented in the PBPK-based simulation workflow and their corresponding system-
specific parameters values
Demographic values
Age 1 day 1 month 6 months 1 year 2 years 5 years 15 years 25 years
Bodyweight, kg 3.45 4.30 7.55 9.90 12.35 18.25 54.25 72.65
Height, cm 49.75 54.25 66.00 74.75 86.00 108.25 166.00 172.30
BSA, m2 0.22 0.26 0.38 0.46 0.55 0.74 1.60 1.86
System-specific parameters
Qh, L/h 6.55 7.83 12.95 17.65 24.65 41.14 89.75 87.92
HSA, g/L 35.78 39.94 42.07 42.90 43.73 44.82 44.68 43.94
AAG, g/L 0.2678 0.5497 0.6774 0.7172 0.7512 0.7877 0.6711 0.6847
Hematocrit, % 51.93 38.14 35.11 35.78 36.79 38.29 40.01 40.74
Liver size, g 133 159 249 313 385 544 1351 1614
MPPGL 25.53 25.60 25.99 26.45 27.36 29.97 36.80 39.79
IO CYP1A2, % 24 35 118 150 164 161 126 100
IO CYP2A6, % 2.1029 0.48 99 100 100 100 100 100
IO CYP2B6, % 15 19 34 47 62 83 99 100
IO CYP2C8, % 38 86 97 99 99 100 100 100
IO CYP2C9, % 40 74 87 90 92 100 100 100
IO CYP2C18–19, % 30 33 84 95 97 98 100 100
IO CYP2D6, % 6 47 84 91 95 98 100 100
IO CYP2E1, % 10 37 59 67 74 82 88 100
IO CYP3A4, % 11 13 48 78 96 104 106 100
IO UGT1A1, % 0.2 23 98 104 100 100 100 100
IO UGT1A4, % 74 74 74 75 77 81 97 100
IO UGT1A6, % 15 30 63 76 87 95 100 100
IO UGT1A9, % 9 12 34 52 71 90 100 100
IO UGT2B7, % 8 9 11 13 18 32 79 100
IO SULT1A1, % 100 100 100 100 100 100 100 100
AAG, alpha-1 acid glycoprotein; BSA, body surface area; HSA, human serum albumin; MPPGL, milligram microsomal protein per gram of liver; IO, isoenzyme
ontogeny expressed as percentage of adult microsomal intrinsic clearance; Qh, hepatic blood flow.
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• Step 1: Data generation
Using the dispersion model (Eqs. 1–6), PBPK-based simulations
of ‘‘true’’ CLp were performed for all hypothetical model drugs M
and test drugs T in adults (‘‘true’’ adult CLp_M and ‘‘true’’ adult
CLp_T, respectively) as well as in each investigated pediatric age
(‘‘true’’ pediatric CLp_M and ‘‘true’’ pediatric CLp_T, respectively).
CLp5CLB3B:P (1)
CLB5Qh3ER (2)
ER512FH (3)
FH5
4a
11að Þ2exp a21ð Þ=2DNf g2 12að Þ2exp 2 a11ð Þ=2DNf g
(4)
a5 114RN3DNð Þ1=2 (5)
RN5 fu=B : Pð Þ3CLint=Qh (6)
In these equations, CLp is the overall total (i.e., bound
and unbound) hepatic plasma clearance, CLB is the total
whole blood clearance, B:P is the blood to plasma ratio, Qh
is the hepatic blood flow, ER is the hepatic extraction ratio,
fu is the unbound drug fraction in plasma, CLint is the total
hepatic intrinsic clearance, RN is the efficiency number, and
DN is the axial dispersion number. For the axial dispersion
number (DN), a value of 0.17 was used.
23 See Supplemen-
tary Material S1 for more details.
• Step 2: Development of pediatric covariate function based on model
drugs M
The pediatric covariate function (f CLp ontogeny_M) describes the
ontogenic changes in ‘‘true’’ CLp from adults to pediatric patients and
is derived from the model drug M. For each model drug M and investi-
gated pediatric postnatal age (AGE), single point estimates of f CLp
ontogeny_M were computed (see equation in Figure 3).
• Step 3: Extrapolation of the pediatric covariate function from model
drugs M to test drugs T
Analogous to Figure 2, scaled pediatric CLp of the test drugs (f
scaled pediatric CLp_T) was computed by scaling the ‘‘true’’ adult
CLp of each test drug T (‘‘true’’ adult CLp_T) to each pediatric age.
This scaling was performed by extrapolating the pediatric covariate
function (f CLp ontogeny_M) from all model drugs to each test drug
following the equation in Figure 3. This led, for each pediatric age
and test drug, to as many scaled pediatric CLps as the number of
model drugs.
• Step 4: Accuracy of the scaled pediatric CLp of the test drug
The prediction errors (PEs) of scaled pediatric CLps obtained in
step 3 was calculated by comparing, for each test drug and each
age, the scaled pediatric CLps with the ‘‘true’’ CLp value obtained in
step 1. This led, for each pediatric age and test drug, to as many
PEs as the number of model drugs. Predictions were considered to
be accurate when the absolute PE was 30% or lower.
Conditions leading to accurate CLp predictions. First, for
the diversity of investigated ages and isoenzymes, trends in
PEs with all drug properties of the model and the test drugs
were separately assessed. These drug properties were the
type of binding plasma protein, Kp, and unbound fraction in
plasma B:P, CLint, and extraction ratio in adults, as well as
the difference in the latter parameters between the model
drug and test drug.
In order to define scenarios consistently leading to accu-
rate CLp scaling from adults to the different pediatric ages
using between-drug extrapolation of pediatric covariate
functions, drug properties allowing to best discriminate
between accurate and inaccurate scaled pediatric CLp were
identified by a hierarchical tree analysis (see Supplementary
Material S1).24
All model-test drug combinations were grouped into scenar-
ios based on the most discriminative drug properties. Within
each of these scenarios, multiple model-test drug combina-
tions are included, and for all combinations, both model and
test drugs are eliminated by the same isoenzyme and binding
to the same plasma protein. Overall accuracy of the test drug
CLp predictions for each model-test drug scenario was sum-
marized per pediatric age group as follows:
• Model-test drug scenario systematically leading to accurate CLp
scaling of the test drug: All CLp predictions within the defined sce-
nario are accurate (absolute PE 30%).
• Model-test drug scenario not systematically leading to accurate CLp
scaling of the test drug: At least one of the CLp predictions within
the defined scenario is inaccurate (absolute PE >30%).
Multiple elimination pathways
Because many drugs are metabolized by multiple isoen-
zymes, we also evaluated the situation in which the model
drug and/or the test drug are metabolized by two isoenzymes,
namely IA and INA. The IA is the isoenzyme representing the
elimination pathway accounted for by the covariate function,
whereas INA is the isoenzyme representing the elimination
pathway not accounted for by the covariate function. In order
to include model drugs and/or test drugs undergoing
Figure 4 The prediction error (PE) of the total (bound and unbound) drug plasma clearance (CLp) predictions for scenarios in which
model and test drugs are exclusively metabolized by one isoenzyme (fmA_adult5100%) and exclusively binding to human serum albu-
min (a) or to alpha-1 acid glycoprotein (b). The boxplots represent the minimum, firth quartile, median, third quartile, and maximum PE
and are categorized by low (green), intermediate (blue), and high (pink) adult extraction ratio (ER) of the model drug and low (light
color), intermediate (intermediate color), and high (dark color) adult extraction ratio of the test drug. For each age, the lowest, interme-
diate, and highest isoenzyme ontogeny values (percentage of adult CLint,mic) reported for the 15 isoenzymes are shown. The interme-
diate isoenzyme ontogeny was defined as the isoenzyme ontogeny value the closest to the mean of the lowest and highest isoenzyme
ontogeny values for a specific age. Low, intermediate, and high extraction ratio correspond to extraction ratio 30%, 30%< extraction
ratio 70% and extraction ratio >70%, respectively. The vertical solid black line indicates a PE of 0. The dotted black and dotted red
lines indicate PE intervals of 1/- 30% and 1/- 50%, respectively. Note that the x-axes are different for different ages.
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metabolism through multiple hepatic isoenzymes, adaptations
of the PBPK-based simulation workflow earlier described
were performed. Details on these alterations can be found in
Supplementary Material S1.
RESULTS
Results for scenarios in which model and test drugs
are metabolized by one isoenzyme
Visual inspection of the PEs revealed trends with age, type
of metabolizing isoenzyme, the type of binding plasma pro-
tein, and extraction ratio in adults of the model drug and
test drug. Figure 4 displays these trends in PEs for all
hypothetical drugs that are exclusively metabolized by one
isoenzyme and that are either exclusively binding to HSA
(Figure 4a) or to AAG (Figure 4b). Results are categorized
by age and by adult extraction ratio category of the model
and test drugs, with increasing absolute PE values indicat-
ing increasing between-drug differences in CLp ontogeny,
with CLp standing for total (i.e., bound and unbound)
hepatic metabolic plasma clearance. For each age, results
are reported for the lowest, intermediate, and highest iso-
enzyme ontogeny values of the 15 isoenzymes included in
the analysis.
Figure 4 shows similar trends in PEs between drugs
binding to HSA and drugs binding to AAG, except in neo-
nates of 1 day of age. However, for AAG bound drugs, the
ranges in PE were either similar or higher than PE ranges
for HSA bound drugs. For both HSA and AAG bound drugs,
the range of absolute PE values tend to decrease with
increasing age. Decreased isoenzyme ontogeny value
tends to increase the range of the absolute PEs, with the
highest absolute PEs being >1,000% in neonates of 1 day
(for isoenzyme ontogeny 0%) and the highest absolute
PE value in adolescents being only about 70% (for isoen-
zyme ontogeny579%).
Generally, within each age category and isoenzyme
ontogeny category, the median PE can be seen to be clos-
est to 0 when extrapolating pediatric covariate models
between drugs of the same extraction ratio category,
although even for these drugs the range in PE values
shows a number of scenarios in which absolute PE values
are higher than 30%. The absolute median PE was the
highest when the model and test drugs belonged to
extreme extraction ratio categories. Except for drugs bind-
ing to AAG in neonates of 1 day old, extrapolating pediatric
covariate functions to a test drug of a lower extraction ratio
category than the model drug systematically yields a
positive median PE, indicating a bias toward overprediction
of CLp of the test drug. The reverse trend is observed
when extrapolating pediatric covariate functions to a test
drug of a higher extraction ratio category than the model
drug. These trends increase as the isoenzyme ontogeny
decreases to values below 100%.
Overall, the hierarchical tree analysis revealed that the
most discriminating drug properties for identifying systemat-
ically accurate CLp predictions across the pediatric age
range were the extraction ratio of the test drug and/or the
model drug, and the difference in extraction ratio and in
unbound fraction in plasma between model drug and test
drug (extraction ratio and unbound fraction defined in
adults, see Supplementary Material S1). The additional
influence of the difference in unbound fraction between the
model drug and test drug on the PEs was not observed
upon visual inspection of the trends in PEs, likely because
trends in PE with unbound fraction are smaller than trends
with extraction ratio and they depend on the extraction ratio
of the model drug and test drug. As the extrapolations to
the test drug require the use of a pediatric covariate model
that is defined for the model drug, scenarios leading to
accurate between-drug extrapolations were defined using
the extraction ratio of the model drug.
These most discriminative drug properties (i.e., extraction
ratio of the model drug, and the difference in extraction
ratio and in unbound fraction between the model drug and
test drug) were used to define model-test drug scenarios
systematically leading to accurate CLp predictions in differ-
ent age ranges, as displayed in the first row of Figure 5a,b
and of the figures in Supplementary Material S2 and S3.
The first row in Figure 5 presents the results for drugs that
are exclusively metabolized by CYP3A4 and that bind to
HSA (Figure 5a) or AAG (Figure 5b), whereas Supple-
mentary Material S2 and S3 show the results for sub-
strates of all investigated isoenzymes binding to HSA and
AAG, respectively. Although the results differ between the
different isoenzymes and plasma proteins, they do reveal
similar trends.
The between-drug extrapolation potential of pathway-
specific pediatric covariate functions generally decreases
with decreasing age, with patterns in model-test drug sce-
narios systematically leading to accurately scaled pediatric
CLp being highly dependent on both ontogeny of the
system-specific parameters and drug properties. For all
ages, the between-drug extrapolation potential increases
with decreasing extraction ratio values of the model drug,
Figure 5 Illustration of model-test drug scenarios that lead to accurate pathway-specific drug plasma clearance (CLp) predictions for a
test drug after between-drug extrapolation of a pathway-specific pediatric covariate function. Results are presented for drugs that are
metabolized by CYP3A4 and that bind to human serum albumin (a) or alpha-1 acid glycoprotein (b). Each column correspond to a
range of extraction ratio (ER) values for the model drug in adults and each row to a specific range of fraction of drug (model and test
drug) that is metabolized by CYP3A4 in adults. For each graph, the y-axis represents the difference in extraction ratio between the test
drug and the model drug (extraction ratio test drug – extraction ratio model drug) in adults, and the x-axis represents the difference in
unbound fraction in plasma between the test drugs and the model drug in adults (unbound fraction test drug – unbound fraction model
drug). Each dot represents a model-test drug scenario, including multiple model-test drug combinations. A color code is used to indi-
cate systematically accurate CLp predictions for all model-test drug combinations within a model-test drug scenario, for children 5
years (yellow), 2 years (pink), 1 year (blue), 6 months (orange), 1 month (purple), and 1 day term neonates (green). Red dots
indicate model-test drug scenarios leading to inaccurate predictions in children older than 5 years for at least one model-test drug com-
bination within the model-test drug scenario. As an example, systematically accurate CLp scaling in children of 6 months and older is
represented by the combination of the green, purple, and orange dots.
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with this effect being most pronounced in younger children
(see Supplementary Material S2 and S3). Moreover, the
extrapolation potential increases when the difference in
extraction ratio between the model and test drugs decreases.
Regarding the plasma protein binding, it can be seen that
between-drug extrapolation of pathway-specific pediatric
covariate functions generally yields more accurately scaled
pediatric CLp for drugs binding to HSA compared with drugs
binding to AAG. Additionally, the difference in plasma protein
binding between the model and test drugs was found to
mostly impact the method applicability in infants of 1 month
or younger.
Results for model drugs and/or test drugs metabolized
by several isoenzymes
When the model drug and/or the test drug are metabolized
by two isoenzymes, the PE increases or decreases, as
compared with drugs eliminated by one isoenzyme depend-
ing on the ontogeny of the isoenzyme representing the
elimination pathway not accounted for by the covariate
model (INA) and the fmA_adult values of the test drug and
model drug. For the specific case in which the isoenzyme
representing the elimination pathway accounted for by the
covariate model (IA) and INA have similar ontogeny, the PEs
are similar to the PE for drugs exclusively metabolized by
one isoenzyme IA.
For model drugs and/or test drugs metabolized by sev-
eral isoenzymes, the most discriminating drug properties to
identify systematically accurate CLp predictions were the
same as those found when both model and test drugs are
metabolized by one unique isoenzyme. However, the larger
the contribution of alternative metabolic pathways to the
overall CLp in adults the lower the extrapolation potential of
the pathway-specific covariate function will be, as can be
seen in the bottom rows of Figure 5 and Supplementary
Material S2 and S3.
DISCUSSION
In this work, we believe for the first time, we systematically
investigated the applicability of between-drug extrapolation
of pathway-specific pediatric covariate functions for CLp of
drugs undergoing hepatic metabolism in which CLp stands
for total (i.e., bound and unbound) hepatic metabolic
plasma clearance. Our results show that pediatric changes
in CLp of drugs that are eliminated by the same hepatic
elimination pathway will not always follow similar patterns
and, therefore, in specific cases, these drugs will require a
different pediatric PK-based dose adjustment.
The CLp ontogeny of a specific elimination pathway was
found to mainly depend on the following drug properties:
the type of binding plasma protein, the adult unbound frac-
tion, and extraction ratio of the drugs, and, in case of multi-
ple elimination pathways, the number and type of
isoenzymes responsible for the drug metabolism. This find-
ing disproves the often implicitly made assumption that the
ontogeny of CLp is drug independent.25,26 Additionally, it
highlights the importance of ontogeny processes other than
isoenzyme ontogeny alone on CLp scaling from adults to
children for drugs undergoing hepatic metabolism (Figure 1).
Therefore, the identified drug properties should be taken into
account when extrapolating pathway-specific pediatric covari-
ate functions between drugs. Figure 5 and Supplementary
Material S2 and S3 were developed to guide the selection of
scenarios that will systematically lead to accurate between-
drug extrapolation of pediatric covariate functions. These
guides can also be interpreted as defining scenarios for which
between-drug extrapolation of pediatric covariate functions
will approximate PBPK-based predictions with an accepted
error of 1/- 30%. In these scenarios, the use of this semime-
chanistic scaling method can be encouraged to expedite pedi-
atric CLp scaling and the development of dosing
recommendations.
To illustrate the use of these guides, we can take the
example of midazolam (extraction ratio5 0.44,27 unbound
fraction in plasma50.02228 with binding to HSA,9 and fm_A
93%28,29), sildenafil (extraction ratio50.45,30 unbound
fraction in plasma 0.04 with binding to HSA,31 and
fm_A5 79%31), and simvastatin (extraction ratio50.97,32
unbound fraction in plasma50.0233 with binding to HSA,34
and fm_A592%29), all mainly metabolized by CYP3A4.
Based on the results for CYP3A4, we can anticipate that
the PopPK covariate model describing CYP3A4-mediated
clearance ontogeny from adults to neonates of 1 day of mida-
zolam could be extrapolated to sildenafil, because the extrac-
tion ratio model50.44, unbound fraction difference50.018,
extraction ratio difference50.01, and fm_A 75% corre-
sponds to a green area in Figure 5a. The same plot also
shows that this extrapolation from midazolam to simva-
statin cannot be performed because the extraction ratio
model50.44, unbound fraction difference520.002, extrac-
tion ratio difference50.53, and fm_A 75% corresponds to a
red area. Importantly, this scaling method is isoenzyme-
specific, and one should be careful not to overlook minor path-
ways in adults that can become major pathways in children
when aiming at scaling total clearance.
It should be noted that model-test drug scenarios leading
to systematically accurate CLp scaling were defined
according to very strict criteria. Each dot in Figure 5 and
the accompanying Supplementary Material S2–S3 repre-
sents a scenario that summarizes the PEs for many differ-
ent model-test drug combinations. The CLp predictions
were defined as not systematically accurate for a scenario
if only one model-test drug combination within this scenario
and, for drugs metabolized by several isoenzymes, if at
least one specific INA (isoenzyme not accounted for by the
covariate model) led to scaled CLp deviating >30% from its
“true” value. However, it is likely for CLp scaling to be accu-
rate for a (large) number of model-test drug combinations
within such scenarios, but in these scenarios the accuracy
of the scaling method cannot be easily predicted a priori
without PBPK modeling.
Overall, our results show that the between-drug extrapo-
lation potential of pathway-specific pediatric covariate func-
tions for CLp increases when the extraction ratio of the
model drug in adults decreases. The applicability of this
method decreases with age and with a decreased adult
fraction of the test drug and/or model drug being metabo-
lized by the isoenzyme pathway accounted for by the
Elimination Pathway and Pediatric Dose Adjustments
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covariate model (fmA_adult). Moreover, these trends
increase with increased extraction ratio of the model drug.
Plasma protein binding to AAG also limits the between-
drug extrapolation potential of pediatric covariate functions
for CLp, especially in young children, which can be
explained by the more pronounced ontogeny pattern of
AAG compared to HSA for these ages.35
In this work, we discovered that, for drugs metabolized
by several isoenzymes, the ontogeny of CLp due to one
specific isoenzyme (IA) is influenced by the ontogeny of the
other isoenzymes responsible for the drug clearance (INA).
We also found that this impact increases with increased
adult extraction ratio and decreased fmA_adult, with
fmA_adult standing for adult fraction of drug CLp due to IA.
This is due to changes in extraction ratio with age contrib-
uted by the ontogeny of all isoenzymes involved in the drug
CLp,36 changes, which, in turn, modify each isoenzyme-
specific CLp ontogenies. This was shown by the reduced
applicability of the between-drug extrapolation potential of
pathway-specific covariate models for CLp with decreased
fmA_adult. This is further supported by the increase of
these trends with increased extraction ratio of the model
drug (see Figure 5 and Supplementary Material S2 and S3).
Although this workflow only investigated drugs undergoing
hepatic metabolic CLp, the results on multiple elimination
routes also apply to drugs undergoing hepatic metabolism in
combination with renal clearance, as renal clearance does
not impact the hepatic extraction ratio or the ontogeny of
hepatic CLp. For these drugs, fmA_adult should be inter-
preted as the fraction of the total hepatic metabolic CLp in
adults due to the isoenzyme pathway accounted for by the
covariate model (IA). Additionally, this workflow can be used
to develop guidance on the need for PK-based dose adjust-
ments in clinical situations of reduced plasma protein bind-
ing, for instance, uremia and hypoalbuminemia, or drug-drug
interactions. In this situation, the model drug properties cor-
respond to the drug properties in normal clinical situations
and the test drug properties are changed to unbound fraction
and extraction ratio values adapted to the calculated values
for plasma protein binding in adults. If such a model-test drug
combination yields an accurate CLp prediction for the test
drug, the pediatric dose can be derived by applying the same
dose adjustment factor used for maintenance doses in adults
with a similar clinical condition.
An important limitation of the PBPK-based simulation
workflow is that active influx or efflux of drugs into or out of
hepatocytes by transporters is not included, thereby implic-
itly assuming this process to be passive. The impact of
active drug transport in the membranes of hepatocytes on
the between-drug extrapolation of pathway-specific pediat-
ric covariate functions requires further investigation.
In conclusion, the developed PBPK-based simulation
workflow utilizing mechanistic equations defining hepatic
metabolism allowed, we believe for the first time, to unravel
the variables most impacting CLp ontogeny and to define
scenarios for which extrapolation of pediatric covariate
functions from one drug to another systematically leads to
accurate isoenzyme-specific CLp scaling from adults to
pediatric patients for 15 hepatic isoenzymes.
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